Julio Aguirre-Ghiso (L) and Alan Rigby (HiberCell)
Looking to reshape the metastatic cancer landscape, HiberCell fills the tank with a slate of mid-stage tests queued up
A little over two years since its last raise, New York-based biotech HiberCell is returning to the venture well for some more capital.
The company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
